Impact of clinico-biochemical and inflammatory biomarkers on the immunogenicity and efficacy of SARS-CoV-2 adenoviral vaccine: a longitudinal study
DOI:
https://doi.org/10.33393/jcb.2023.2480Keywords:
COVID-19, CRP, IgG, LDH, SARS-CoV-2, Spike protein, Total antibodies, VaccinesAbstract
Purpose: Due to a lack of effective antiviral treatment, several vaccines have been put forth to curb SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) infection and to reduce the mortality and morbidity rate by eliciting a protective immune response, primarily through virus-neutralizing antibodies specific for SARS-CoV-2 spike protein. This longitudinal study was designed to evaluate the vaccine effectiveness and immune response following the administration of adenoviral vaccine, COVISHIELD, in Indian population who were previously uninfected with SARS-CoV-2 and to reveal the effect of various sociodemographic, inflammatory and biochemical factors on antibody response.
Methods: Briefly, the total immunoglobulin G (IgG) against SARS-CoV-2 spike and nucleocapsid protein along with the immunological markers were estimated by chemiluminescent microparticle immunoassay (CMIA) technology. Biochemical parameters were estimated by spectrometry.
Results: A total of 348 subjects received two doses of COVISHIELD (224 males, 124 females). The mean age of the study subjects was 42.03 ± 13.54 years. Although both the doses of COVISHIELD against SARS-CoV-2 spike protein induced a robust immune response that lasted for months in all the subjects, the total IgG titer against SARS-CoV-2 spike protein was found significantly higher in subjects ≥50 years of age, and those with obesity, elevated triglycerides and elevated lactate dehydrogenase levels.
Conclusions: There is a definite effect of age and biochemical factors on the immunogenicity of COVISHIELD. An understanding of these factors could not only impact the design of vaccines and help improve vaccine immunogenicity and efficacy but also assist in decisions on vaccination schedules, in order to combat this deadly pandemic.
Downloads
References
Majid S, Khan MS, Rashid S, et al. COVID-19: diagnostics, therapeutic advances, and vaccine development. Curr Clin Microbiol Rep. 2021;8(3):152-166. https://doi.org/10.1007/s40588-021-00157-9 PMID:33614398 DOI: https://doi.org/10.1007/s40588-021-00157-9
Farooq R, Majid S, Hanif A, Qureshi W. Current insights into the coronavirus: genomics of 2019-nCoV. Clin Med Case Rep. 2020;3:03-1.
COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). https://coronavirus.jhu.edu/map.html. Accessed April 20, 2022.
COVID19 Statewise Status. https://www.mygov.in/corona-data/covid19-statewise-status/. Accessed April 20, 2022.
COVID-19 Vaccination Update. Ministry of Health and Family Welfare: Government of India.https://www.mohfw.gov.in/covid_vaccination/vaccination/index.html. Accessed April 20, 2022.
Majid S, Farooq R, Khan MS, et al. Managing the COVID-19 pandemic: research strategies based on the evolutionary and molecular characteristics of coronaviruses. SN Compr Clin Med. 2020;2(10):1767-1776. https://doi.org/10.1007/s42399-020-00457-z PMID:32864575 DOI: https://doi.org/10.1007/s42399-020-00457-z
Voysey M, Clemens SAC, Madhi SA, et al; Oxford COVID Vaccine Trial Group. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99-111. https://doi.org/10.1016/S0140-6736(20)32661-1 PMID:33306989 DOI: https://doi.org/10.1016/S0140-6736(20)32661-1
Bharat Biotech Announces Phase 3 Results of COVAXIN®: India’s First COVID-19 Vaccine Demonstrates Interim Clinical Efficacy of 81%. https://indiaeducationdiary.in/bharat-biotech-announces-phase-3-results-of-covaxin-indias-first-covid-19-vaccine-demonstrates-interim-clinical-efficacy-of-81/. Accessed April 20, 2022.
Klausegger A, Strobl B, Regl G, Kaser A, Luytjes W, Vlasak R. Identification of a coronavirus hemagglutinin-esterase with a substrate specificity different from those of influenza C virus and bovine coronavirus. J Virol. 1999;73(5):3737-3743. https://doi.org/10.1128/JVI.73.5.3737-3743.1999 PMID:10196267 DOI: https://doi.org/10.1128/JVI.73.5.3737-3743.1999
Wang Z, Schmidt F, Weisblum Y, et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature. 2021;592(7855):616-622. https://doi.org/10.1038/s41586-021-03324-6 PMID:33567448 DOI: https://doi.org/10.1038/s41586-021-03324-6
Khan SMS, Qurieshi MA, Haq I, et al. Seroprevalence of SARS-CoV-2-specific IgG antibodies in Kashmir, India, 7 months after the first reported local COVID-19 case: results of a population-based seroprevalence survey from October to November 2020. BMJ Open. 2021;11(9):e053791. https://doi.org/10.1136/bmjopen-2021-053791 PMID:34556519 DOI: https://doi.org/10.1136/bmjopen-2021-053791
Haq I, Qurieshi MA, Khan MS, et al. The burden of SARS-CoV-2 among healthcare workers across 16 hospitals of Kashmir, India—a seroepidemiological study. PLoS One. 2021 Nov 19;16(11):e0259893. https://doi.org/10.1371/journal.pone.0259893 PMID: 34797880 DOI: https://doi.org/10.1371/journal.pone.0259893
Chen H, Xiang ZQ, Li Y, et al. Adenovirus-based vaccines: comparison of vectors from three species of adenoviridae. J Virol. 2010;84(20):10522-10532. https://doi.org/10.1128/JVI.00450-10 PMID:20686035 DOI: https://doi.org/10.1128/JVI.00450-10
Wall EC, Wu M, Harvey R, et al. Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination. Lancet. 2021;397(10292):2331-2333. https://doi.org/10.1016/S0140-6736(21)01290-3 PMID:34090624 DOI: https://doi.org/10.1016/S0140-6736(21)01290-3
Wang P, Nair MS, Liu L, et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature. 2021;593(7857):130-135. https://doi.org/10.1038/s41586-021-03398-2 PMID:33684923 DOI: https://doi.org/10.1038/s41586-021-03398-2
Pellini R, Venuti A, Pimpinelli F, et al. Initial observations on age, gender, BMI and hypertension in antibody responses to SARS-CoV-2 BNT162b2 vaccine. EClinicalMedicine. 2021;36:100928. https://doi.org/10.1016/j.eclinm.2021.100928 PMID:34109307 DOI: https://doi.org/10.1016/j.eclinm.2021.100928
Zimmermann P, Curtis N. Factors that influence the immune response to vaccination. Clin Microbiol Rev. 2019;32(2):e00084-e00118. https://doi.org/10.1128/CMR.00084-18 PMID:30867162 DOI: https://doi.org/10.1128/CMR.00084-18
Brusselle GG, Joos GF, Bracke KR. New insights into the immunology of chronic obstructive pulmonary disease. Lancet. 2011;378(9795):1015-1026. https://doi.org/10.1016/S0140-6736(11)60988-4 PMID:21907865 DOI: https://doi.org/10.1016/S0140-6736(11)60988-4
Drummond GR, Vinh A, Guzik TJ, Sobey CG. Immune mechanisms of hypertension. Nat Rev Immunol. 2019;19(8):517-532. https://doi.org/10.1038/s41577-019-0160-5 PMID:30992524 DOI: https://doi.org/10.1038/s41577-019-0160-5
Berbudi A, Rahmadika N, Tjahjadi AI, Ruslami R. Type 2 diabetes and its impact on the immune system. Curr Diabetes Rev. 2020;16(5):442-449. https://doi.org/10.2174/18756417MTAxgODQqy PMID:31657690 DOI: https://doi.org/10.2174/1573399815666191024085838
Painter SD, Ovsyannikova IG, Poland GA. The weight of obesity on the human immune response to vaccination. Vaccine. 2015;33(36):4422-4429. https://doi.org/10.1016/j.vaccine.2015.06.101 PMID:26163925 DOI: https://doi.org/10.1016/j.vaccine.2015.06.101
Vandanmagsar B, Youm YH, Ravussin A, et al. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat Med. 2011;17(2):179-188. https://doi.org/10.1038/nm.2279 PMID:21217695 DOI: https://doi.org/10.1038/nm.2279
Milner JJ, Beck MA. The impact of obesity on the immune response to infection. Proc Nutr Soc. 2012;71(2):298-306. https://doi.org/10.1017/S0029665112000158 PMID:22414338 DOI: https://doi.org/10.1017/S0029665112000158
Pedersen SF, Ho YC. SARS-CoV-2: a storm is raging. J Clin Invest. 2020;130(5):2202-2205. https://doi.org/10.1172/JCI137647 PMID:32217834 DOI: https://doi.org/10.1172/JCI137647
Kermali M, Khalsa RK, Pillai K, Ismail Z, Harky A. The role of biomarkers in diagnosis of COVID-19—a systematic review. Life Sci. 2020;254:117788. https://doi.org/10.1016/j.lfs.2020.117788 PMID:32475810 DOI: https://doi.org/10.1016/j.lfs.2020.117788
Tanaka T, Kishimoto T. The biology and medical implications of interleukin-6. Cancer Immunol Res. 2014;2(4):288-294. https://doi.org/10.1158/2326-6066.CIR-14-0022 PMID:24764575 DOI: https://doi.org/10.1158/2326-6066.CIR-14-0022
Szalai AJ, van Ginkel FW, Dalrymple SA, Murray R, McGhee JR, Volanakis JE. Testosterone and IL-6 requirements for human C-reactive protein gene expression in transgenic mice. J Immunol. 1998;160(11):5294-5299. https://doi.org/10.4049/jimmunol.160.11.5294 PMID:9605127 DOI: https://doi.org/10.4049/jimmunol.160.11.5294
Zhang L, Liu SH, Wright TT, et al. C-reactive protein directly suppresses Th1 cell differentiation and alleviates experimental autoimmune encephalomyelitis. J Immunol. 2015;194(11):5243-5252. https://doi.org/10.4049/jimmunol.1402909 PMID:25917100 DOI: https://doi.org/10.4049/jimmunol.1402909
Gray CP, Franco AV, Arosio P, Hersey P. Immunosuppressive effects of melanoma-derived heavy-chain ferritin are dependent on stimulation of IL-10 production. Int J Cancer. 2001;92(6):843-850. https://doi.org/10.1002/ijc.1269 PMID:11351305 DOI: https://doi.org/10.1002/ijc.1269
Naaber P, Tserel L, Kangro K, et al. Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study. Lancet Reg Health Eur. 2021;10:100208. https://doi.org/10.1016/j.lanepe.2021.100208 PMID:34514454 DOI: https://doi.org/10.1016/j.lanepe.2021.100208
Collier DA, Ferreira IATM, Kotagiri P, et al; CITIID-NIHR BioResource COVID-19 Collaboration. Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2. Nature. 2021;596(7872):417-422. https://doi.org/10.1038/s41586-021-03739-1 PMID:34192737 DOI: https://doi.org/10.1038/s41586-021-03739-1
Ciabattini A, Nardini C, Santoro F, Garagnani P, Franceschi C, Medaglini D. Vaccination in the elderly: the challenge of immune changes with aging. Semin Immunol. 2018;40:83-94. https://doi.org/10.1016/j.smim.2018.10.010 PMID:30501873 DOI: https://doi.org/10.1016/j.smim.2018.10.010
Alpert A, Pickman Y, Leipold M, et al. A clinically meaningful metric of immune age derived from high-dimensional longitudinal monitoring. Nat Med. 2019;25(3):487-495. https://doi.org/10.1038/s41591-019-0381-y PMID:30842675 DOI: https://doi.org/10.1038/s41591-019-0381-y
Bartleson JM, Radenkovic D, Covarrubias AJ, Furman D, Winer DA, Verdin E. SARS-CoV-2, COVID-19 and the aging immune system. Nat Aging. 2021;1(9):769-782. https://doi.org/10.1038/s43587-021-00114-7 PMID:34746804 DOI: https://doi.org/10.1038/s43587-021-00114-7
Weisberg SP, Connors TJ, Zhu Y, et al. Distinct antibody responses to SARS-CoV-2 in children and adults across the COVID-19 clinical spectrum. Nat Immunol. 2021;22(1):25-31. https://doi.org/10.1038/s41590-020-00826-9 PMID:33154590 DOI: https://doi.org/10.1038/s41590-020-00826-9
Stiasny K, Aberle JH, Keller M, Grubeck-Loebenstein B, Heinz FX. Age affects quantity but not quality of antibody responses after vaccination with an inactivated flavivirus vaccine against tick-borne encephalitis. PLoS One. 2012;7(3):e34145. https://doi.org/10.1371/journal.pone.0034145 PMID:22461903 DOI: https://doi.org/10.1371/journal.pone.0034145
McQuillan GM, Kruszon-Moran D, Hyde TB, Forghani B, Bellini W, Dayan GH. Seroprevalence of measles antibody in the US population, 1999-2004. J Infect Dis. 2007;196(10):1459-1464. https://doi.org/10.1086/522866 PMID:18008224 DOI: https://doi.org/10.1086/522866
Christy C, Pichichero ME, Reed GF, et al. Effect of gender, race, and parental education on immunogenicity and reported reactogenicity of acellular and whole-cell pertussis vaccines. Pediatrics. 1995;96(3 Pt 2):584-587. https://doi.org/10.1542/peds.96.3.584 PMID:7659481 DOI: https://doi.org/10.1542/peds.96.3.584
Stein CM, Guwatudde D, Nakakeeto M, et al. Heritability analysis of cytokines as intermediate phenotypes of tuberculosis. J Infect Dis. 2003;187(11):1679-1685. https://doi.org/10.1086/375249 PMID:12751024 DOI: https://doi.org/10.1086/375249
Brodin P, Davis MM. Human immune system variation. Nat Rev Immunol. 2017;17(1):21-29. https://doi.org/10.1038/nri.2016.125 PMID:27916977 DOI: https://doi.org/10.1038/nri.2016.125
Serena C, Keiran N, Ceperuelo-Mallafre V, et al. Obesity and type 2 diabetes alters the immune properties of human adipose derived stem cells. Stem Cells. 2016;34(10):2559-2573. https://doi.org/10.1002/stem.2429 PMID:27352919 DOI: https://doi.org/10.1002/stem.2429
Mraz M, Haluzik M. The role of adipose tissue immune cells in obesity and low-grade inflammation. J Endocrinol. 2014;222(3):R113-R127. https://doi.org/10.1530/JOE-14-0283 PMID:25006217 DOI: https://doi.org/10.1530/JOE-14-0283
Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 1993;259(5091):87-91. https://doi.org/10.1126/science.7678183 PMID:7678183 DOI: https://doi.org/10.1126/science.7678183
Fried SK, Bunkin DA, Greenberg AS. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab. 1998;83(3):847-850. https://doi.org/10.1210/jc.83.3.847 PMID:9506738 DOI: https://doi.org/10.1210/jc.83.3.847
Liu R, Nikolajczyk BS. Tissue immune cells fuel obesity-associated inflammation in adipose tissue and beyond. Front Immunol. 2019;10:1587. https://doi.org/10.3389/fimmu.2019.01587 PMID:31379820 DOI: https://doi.org/10.3389/fimmu.2019.01587
Callahan ST, Wolff M, Hill HR, et al; NIAID Vaccine and Treatment Evaluation Unit (VTEU) Pandemic H1N1 Vaccine Study Group. Impact of body mass index on immunogenicity of pandemic H1N1 vaccine in children and adults. J Infect Dis. 2014;210(8):1270-1274. https://doi.org/10.1093/infdis/jiu245 PMID:24795475 DOI: https://doi.org/10.1093/infdis/jiu245
Sheridan PA, Paich HA, Handy J, et al. Obesity is associated with impaired immune response to influenza vaccination in humans. Int J Obes. 2012;36(8):1072-1077. https://doi.org/10.1038/ijo.2011.208 PMID:22024641 DOI: https://doi.org/10.1038/ijo.2011.208
Lundman P, Eriksson MJ, Silveira A, et al. Relation of hypertriglyceridemia to plasma concentrations of biochemical markers of inflammation and endothelial activation (C-reactive protein, interleukin-6, soluble adhesion molecules, von Willebrand factor, and endothelin-1). Am J Cardiol. 2003;91(9):1128-1131. https://doi.org/10.1016/S0002-9149(03)00165-6 PMID:12714163 DOI: https://doi.org/10.1016/S0002-9149(03)00165-6
Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. Biochem J. 1990;265(3):621-636. https://doi.org/10.1042/bj2650621 PMID:1689567 DOI: https://doi.org/10.1042/bj2650621
Ma SD, Mussbacher M, Galkina EV. Functional role of B cells in atherosclerosis. Cells. 2021;10(2):270. https://doi.org/10.3390/cells10020270 PMID:33572939 DOI: https://doi.org/10.3390/cells10020270
Xu DM, Li Q, Yi JX, et al. Investigation of lymphocyte subsets in peripheral blood of patients with dyslipidemia. Int J Gen Med. 2021;14:5573-5579. https://doi.org/10.2147/IJGM.S326628 PMID:34548808 DOI: https://doi.org/10.2147/IJGM.S326628
Wang L, Sapuri-Butti AR, Aung HH, Parikh AN, Rutledge JC. Triglyceride-rich lipoprotein lipolysis increases aggregation of endothelial cell membrane microdomains and produces reactive oxygen species. Am J Physiol Heart Circ Physiol. 2008;295(1):H237-H244. https://doi.org/10.1152/ajpheart.01366.2007 PMID:18487440 DOI: https://doi.org/10.1152/ajpheart.01366.2007
Sepulveda J. Challenges in routine clinical chemistry analysis: proteins and enzymes. In: Dasgupta A, Sepulveda JL, eds. Accurate results in the clinical laboratory. Elsevier 2013: 131-148. https://www.sciencedirect.com/science/article/abs/pii/B9780124157835000098 DOI: https://doi.org/10.1016/B978-0-12-415783-5.00009-8
McFadden RG, Oliphant LD. Serum lactate dehydrogenase in interstitial lung disease. Chest. 1991;100(4):1182. https://doi.org/10.1378/chest.100.4.1182-b PMID:1914596 DOI: https://doi.org/10.1378/chest.100.4.1182-b
Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392(6673):245-252. https://doi.org/10.1038/32588 PMID:9521319 DOI: https://doi.org/10.1038/32588
Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med. 1994;179(4):1109-1118. https://doi.org/10.1084/jem.179.4.1109 PMID:8145033 DOI: https://doi.org/10.1084/jem.179.4.1109
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Sabhiya Majid, Mosin Saleem Khan, Najila Nisar, Javid A Bhat, Inaamul Haq, S Muhammad Salim Khan
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors contributing to Journal of Circulating Biomarkers agree to publish their articles under the Creative Common Attribution Non Commercial 4.0 (CC-BY-NC 4.0) license, which allows third parties to re-use the work without permission as long as the work is properly referenced and the use is non-commercial.
Accepted 2023-09-04
Published 2023-09-20
